Context Therapeutics
Philadelphia
About Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company dedicated to creating new medicines to treat hormone-responsive cancers. Context’s lead program is Apristor (Onapristone XR), an investigational Phase 2 drug that is being developed for progesterone receptor positive (PR+) metastatic breast and ovarian cancers. In addition, Context is advancing CTX-030916, a potential best-in-class oral antiprogestin for the treatment of uterine fibroids and endometriosis, and a discovery-stage program targeting Sigma1.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $131.2M
- Funding stage: IPO
- Last round: Post-IPO Equity (May 2024)
- Ticker: nasdaq:CNTX
- Website: contexttherapeutics.com
Industries & Categories
Biotechnology, Health Care
Social Profiles
Canonical: https://fsome.com/organization/context-therapeutics-26337 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.